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ABSTRACT 
 
COMPARING THE MULTIDIMENSIONAL BEHAVIORAL HEALTH SCREEN TO THE 
PHQ-9 IN PREDICTING DEPRESSION-RELATED SYMPTOMATOLOGY IN A PRIMARY 
MEDICAL CARE SAMPLE 
 
Hannah Gabrielle Mitchell, B.A. 
Western Carolina University (March 2019) 
Director: Dr. David McCord 
 
Depression is the most common form of psychopathology affecting people in the US. It is 
commonly diagnosed and treated in primary medical care settings, creating a need for a reliable, 
quick self-report tool used for the assessment of depression in this context. There is a current 
shift in the way psychopathology is conceptualized, as the field transitions from a categorical, 
syndrome-based model to a dimensional model. This transition should be reflected in the 
assessment tool used within the primary care setting. The Multidimensional Behavioral Health 
Screen is being developed as a brief and efficient screening-level assessment tool for core 
psychopathology components (rather than syndromes), with a specific focus on depressive 
symptomatology. This study presents empirical evidence supporting the implementation of the 
MBHS as a reliable and valid mental health screener to be administered in primary care clinics. 
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INTRODUCTION 
Assessment and Treatment of Depression 
Depression is one of the most prevalent mental illnesses, with 6.7% of all U.S. adults 
experiencing at least one major depressive episode in their lifetime (NIMH, 2016). Women are 
particularly prone to experiencing depression, with roughly 8.5% of women in the US 
experiencing symptoms of depression (NIMH, 2016). Furthermore, depression is the leading 
cause of suicide, which accounts for 1.4% of all deaths worldwide, or 13.4 deaths per 100,000 
people in the US. (WHO, 2017). The rate of suicide in the US has been increasing since 1999, 
creating a need for significant and immediate identification and interventions for people 
experiencing depressive symptoms (Kegler, Stone, & Holland, 2017). 
Most people in the US who seek help for depression receive it from their primary care 
physician rather than a mental health professional (Magellen Healthcare, 2014). Depression is 
indicated as a reason for a visit to a primary care physician 10.3% of the time (CDC, 2017). In 
primary care settings, the Patient Health Questionnaire-9 (PHQ-9) is one of the most frequently 
used tools for assessing and diagnosing depression (Spitzer, Kroenke, & Williams, 1999). The 
PHQ-9 is a 9-item self-report questionnaire which mirrors the DSM-5 criteria for depression. For 
each item, participants answer on a scale of “0” (not at all) to “3” (nearly every day) how often 
they are bothered by the 9 symptoms of depression. See appendix B for a copy of the PHQ-9. 
The PHQ-9 has been found to be psychometrically sound when comparing patient’s 
scores to their eligibility for DSM-5 criteria for depression. One study which collected data on 
580 participants found the internal reliability of the PHQ-9 to be excellent, with a Cronbach's α 
of 0.89 (Kroenke, Spitzer, Williams, 2001). The same study found the test-retest reliability of the 
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PHQ-9 to be very strong. The correlation between the results of the PHQ-9 and diagnosis arrived 
at after a structured clinical interview was 0.84, and the mean scores from each assessment were 
nearly identical (Kroenke, Spitzer, Williams, 2001).  
While the PHQ-9 is a reliable and valid screening tool psychometrically, it still exhibits 
shortcomings when used in a clinical setting; specifically, it lumps many heterogeneous 
symptoms into a single syndrome. Furthermore, since a depression diagnosis requires presence 
of only five of the nine symptoms listed in the DSM-5, it is possible for two people diagnosed 
with clinical depression to share only one symptom. This is problematic as it does not identify 
and parse out people who will benefit from any one of the many different treatments for 
depressive symptoms.  
Depression is commonly treated with a selective serotonin reuptake inhibitor (SSRI) 
medication, targeting a depletion of the neurotransmitter serotonin in the central nervous system 
(Delgado & Moreno, 2000). The use of SSRIs as a treatment option is based on the monoamine 
theory, which suggests that the pathophysiologic source of depression is an insufficient supply of 
serotonin, norepinephrine, and/or dopamine in the synapses of the brain (Coppen, 1967). SSRIs 
counteract this effect by blocking the reuptake of serotonin, thus increasing the neurotransmitter 
in the synapse. 
Advancing beyond the monoamine theory, more recent clinical studies have provided 
evidence of neuronal atrophy in response to stress and depression. Prolonged exposure to stress 
results in the release of glucocorticoids, such as cortisol, in the synapses (Duman, Malberg, 
Nakagawa, D’Sa, 2000). The oversupply of cortisol may be sufficient to cause damage to brain 
cells. In addition to the detrimental effect of cortisol, stress is also found to diminish brain-
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derived neurotrophic factor (BDNF) in the hippocampus (Smith et al., 1995). Decreased levels of 
BDNF are found to decrease the survival and function of neurons in the adult brain, as well as 
limit neural plasticity. 
There is evidence to suggest that antidepressant treatment increases the expression of 
BDNF, which decreases the rates of cell death (Duman et al., 1999). Through stimulating BDNF 
antidepressant treatment may increase neurogenesis, facilitating the growth and development of 
neurons (Duman, Malberg, Nakagawa, & D’Sa, 2000). Recent studies demonstrate that chronic 
antidepressant treatment increases neurogenesis, which in turn increases the proliferation and 
survival of new neurons (Duman, Malberg, Nakagawa, & D’Sa, 2000). 
Just as depression is most often diagnosed in a primary care setting, antidepressant 
medications are typically prescribed by a primary care physician rather than a psychiatrist. The 
rate of prescriptions being written for SSRI medications have increased dramatically in the last 
two decades. Presently 7% percent of all visits to a primary care physician end with a 
prescription for an SSRI medication. This is compared to 1997, when only 3% of primary care 
office visits resulted in a SSRI prescription. SSRI drugs are now the second most commonly 
prescribed drug in the US (Mojtabai & Olfson, 2011).  
Despite the frequent prescription of SSRIs, their effectiveness is widely disputed. 
According to one meta-analysis utilizing FDA data, only 51% of studies examining 
antidepressants produced a positive result (Kirsch, 2008). For people with mild or moderate 
depression, one meta-analysis found SSRI treatment to have a nonexistent to minimal effect on 
depressive symptoms (Fournier et al., 2010). Another study, while finding SSRIs to be superior 
to placebo treatment, found that roughly 24% of people prescribed an SSRI did not respond to 
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treatment (Gueorguieva, 2011). Not only is non-response a possible downfall of taking an SSRI, 
but as many as 25% of people experience a worsening of symptoms while taking the drug 
compared to placebo (Juurlink, 2006; Kirsch, 2008). 
The problem with prescribing an antidepressant to someone who will likely not benefit 
from it is that SSRIs are sometimes accompanied by detrimental side effects. The most common 
side effect is gastrointestinal (GI) disturbances (Goldstein & Goodnick, 1998). Other harmful 
side effects include sexual dysfunction, insomnia, skin rashes, headaches, joint and muscle pain, 
and nausea (Harvard Health, 2014). In some cases, particularly in adolescents and adults under 
the age of 25, antidepressant use can lead to suicidal thoughts or actions (Fergusson et al., 2005). 
Therefore, it is important for prescribers to be selective and cautious when deciding to place 
someone on an antidepressant. 
What explains the lack of efficacy of SSRIs for a significant minority of patients? 
Perhaps people with certain types of depression may benefit from SSRIs while people with other 
types of depression may not. It may be that the monoamine theory is insufficient in explaining 
depressive symptoms for people who experience demoralization due to circumstances in life 
such as poor work and family relationships. Therefore, people with those depressive symptoms 
will likely benefit more from psychotherapy than an SSRI, which would only target chemical 
imbalances and perhaps not the source of the person’s despair. In contrast, other depressive 
symptoms may have a more neurological basis; thus, people experiencing them may benefit the 
most from an SSRI medication. People suffering from anhedonia, a symptom of depression 
manifested by lack of pleasure and interest in previously enjoyable activities, may be an example 
of a group who would benefit from an SSRI.  
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There is substantial evidence to suggest that anhedonia is associated with a deficit in 
hedonic capacity, a specific neurological reward circuit (Pizzagalli, Iosifescu, Hallett, Ratner, & 
Fava, 2008). Furthermore, the neurobiological mechanisms which influence hedonic capacity are 
not necessarily involved in other reward deficits, such as those found in non-anhedonic people 
with depression (Der-Avakian & Markou, 2012). The μ-opioid and endocannabinoid receptors in 
the nucleus accumbens and ventral pallidum are the critical regions for hedonic capacity to occur 
(Der-Avakian & Markou, 2012). There are drugs which specifically target restoring hedonic 
capacity to control levels, specifically nonmonoamine antidepressants (Katzman & Sternat, 
2016). When designing a successful depression inventory, a key feature will be identifying 
which of the differential core components of depression the patient is experiencing, and in turn 
using that information to create a successful treatment plan. 
Current Paradigm Shifts within Psychology 
An important shift in the current understanding of mental illness is the transition from 
categorical diagnoses to a dimensional understanding of pathological symptomology. 
Dimensions may be thought of as continua which reflect the adaptive and maladaptive 
characteristics of the entire population, with one end experiencing none of the symptoms and the 
other end presenting extreme prevalence of the symptoms (Kotov, 2017). This view is contrasted 
with the current mode of diagnostic thinking, in which mental illness is thought of as a fixed 
entity. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5) utilizes a categorical 
approach of classifying mental illness.  
Several limitations exist for the current classification system of mental illness. First, 
interrater reliability is very low, with 40% of DSM-5 based diagnoses not meeting adequate 
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interrater reliability levels (Regier et al., 2013). Secondly, comorbidity for mental disorders is 
highly prevalent, with 45% of people with one mental disorder meeting criteria for two or more 
other mental disorders. High levels of comorbidity in mental disorders suggests an extent to 
which the divisions between conditions are arbitrary. If an individual is experiencing two 
“comorbid disorders,” it may be more accurate to conceptualize the individual’s difficulties as a 
conglomeration of symptoms which are not distinct from each other. The imprecise current 
method of diagnosing mental illness both hinders proper treatment considerations and limits 
research. The solution to the shortfalls inherent within categorical diagnoses lies within the 
empirically-based dimensional understanding of mental symptomology.  
Several models of psychopathology have adopted a dimensional conceptualization of 
syndromes. One such model is included as an emerging model in Section III of the DSM-5, 
which covers personality disorders.  The proposed model for assessing personality disorders 
includes two criteria: criterion A: significant impairments in self identity or self-direction and 
interpersonal functioning and criterion B: one or more pathological personality trait domains, 
based on a dimensional understanding of personality traits (Few et al., 2013). Utilizing the DSM-
5 Section III approach, clinicians rate individuals on 25 dimensional traits and four impairment 
domains. Research has provided evidence supporting the reliability and validity of the DSM-5 
section III approach to personality disorders (Few et al., 2013).  
The Research Domain Criteria (RDoC) project was created by the National Institute of 
Mental Health as a way of classifying mental pathology through dimensions of observable 
behavior and neurobiology (Cuthbert & Insel, 2010, 2013). RDoC employs the following 6 
domains to classify pathology: cognitive, positive valence, negative valence, social processes, 
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arousal, and regulatory systems. The aim of RDoC is to create a framework for researchers to 
operate under which has eliminated the heterogeneity between mental disorders and focuses on 
individual dimensions (Cuthbert & Insel, 2010, 2013). 
Most recently, the Hierarchical Taxonomy of Psychopathology (HiTOP) has been created 
as a dimensional alternative to categorical understandings of mental pathology (Kotov, et al., 
2017). The HiTOP classification system proposes that mental traits occur as a continuum across 
multiple levels of a hierarchy. The hierarchical view allows clinicians to view pathology as 
graded, with symptoms ranging from broad to narrow in scope. 
 The Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF; 
Ben-Porath & Tellegen, 2008/2011) operates under a dimensional view of mental illness and is 
one of the most widely used instruments for assessing psychopathology worldwide (Drayton, 
2009). The MMPI-2-RF consists of 338 self-report questions designed to conceptualize a 
person’s psychological state and personality. Interpretation of the 338 questions is broken down 
into five content domains: Somatic/Cognitive, Emotional/Internalizing, Thought Dysfunction, 
Behavioral/Externalizing, and Interpersonal Functioning. Within the five domains exist three 
tiers: broad, mid-level, and narrow (see Figure 1). Within the Emotional/Internalizing 
dysfunctional domain are the two noteworthy mid-level scales of Demoralization (RCd) and 
Anhedonia (RC2). RC2 measures what is commonly described as anhedonia, with high levels on 
this scale indicating a lack of feelings of pleasure. RCd, in contrast, measures general distress 
and discontentment. In the DSM-5, there exists no distinction between RCd and RC2 symptoms 
when considering the diagnosis of depression. However, the segregation of depressed mood and 
anhedonia in the MMPI-2-RF is crucial for selecting the most appropriate treatment plan.  
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A 3-factor model of internalizing dysfunction has been proposed by Watson and has 
additional support by Sellbom, Ben-Porath, and Bagby (Sellbom, Ben-Porath & Bagby, 2008; 
Watson, Gamez, & Simms, 2005). Rather than focusing on traditional categorical disorders such 
as anxiety and depression, this method organizes the broad internalizing dysfunction domain into 
the three factors of anxious-misery, anhedonia, and fear. The MMPI-2-RF assesses these three 
factors separately through the scales RCd, RC2, and RC7, respectively.  
Implications of the Dimensional Model for Behavioral Health Screening 
As noted above, the PHQ-9, while used widely, is based on the traditional, categorical 
paradigm. The categorical model of pathology makes creating a short, accurate screening test 
very difficult. With the shift to a dimensional model of psychopathology, there is now an 
opportunity to create a more precise assessment tool. Benefits of a dimensional assessment tool 
include its precise estimation of a trait, as validated by the MMPI-2-RF, and its exclusion of 
heterogeneous symptoms.  
Therefore, there is a pressing need to create a self-report measure which will quickly 
evaluate patients within primary care clinic for maladaptive psychological symptoms. The 
Multidimensional Behavioral Health Screen (MBHS) is an assessment tool currently being 
validated. It is designed to correlate highly with the following nine of the MMPI-2RF’s mid-
level and narrow constructs: Somatization (RC1), Demoralization (RCd), Anhedonia (RC2), 
Anxiety (RC7), Suicide/Death Ideation (SUI), Cognitive complaints (COG), Activation (ACT), 
Disconstraint (DISC-r), and Substance Abuse (SUB).  
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Table 1: Comparing MBHS and MMPI-2-RF terminology with description 
MBHS Scale MMPI-2-RF Target Scale Brief Description 
Somatization 
SOMs 
Somatic Complaints 
RC1 
A variety of physical symptoms, 
including gastric, headache, 
neurological 
Demoralization 
DEMs 
Demoralization 
RCd 
General unhappiness, dissatisfaction 
with life 
Anhedonia 
ANHs 
Anhedonia 
RC2 
Low positive emotion, joylessness 
Anxiety 
ANXs 
Dysfunctional Negative 
Emotions 
RC7 
Fear, worry 
Suicide/Death 
Ideation 
SUIs 
Suicide/Death Ideation 
SUI 
Suicidal or death-oriented thoughts, 
tendencies, or attempts 
Cognitive 
Complaints 
COGs 
Cognitive Complaints 
COG 
Attention, concentration, focus and 
memory difficulties 
Activation 
ACTs 
Activation 
ACT 
Energy, restlessness 
Disconstraint 
DSCs 
Disconstraint 
DISC-r 
Impulsivity, low self-control 
Substance Abuse 
SUBs 
Substance Abuse 
SUB 
Drug abuse, including alcohol 
 
 
Depressive symptomatology is the priority and primary focus of this assessment tool, as it 
is commonly seen in primary care offices. However, this tool may be used to assess for other 
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behavioral health problems, including anxiety-related problems and attention/cognitive 
problems. The scale also includes screening measures of two specific issues relevant to any 
healthcare provider, suicidal ideas and substance abuse. 
Somatization estimates the extent to which psychological factors may be contributing to 
the patient’s complaints of physical symptomatology. Demoralization measures general 
unhappiness and dissatisfaction with their life and may be most improved through 
psychotherapy. Anhedonia measures an overall lack of enjoyment in completing pleasurable 
activities and may be positively affected by the administration of medication. As noted above, 
the distinction between Demoralization and Anhedonia is important in the treatment of 
depression. It is separated in the MMPI-2-RF and thus will be screened for separately in the 
MBHS. The anxiety scale was chosen for screening purposes because of the common 
cooccurrence of anxiety with a host of other mental and physical problems. Suicide/death 
ideation assessment is crucial for assessing a patient’s safety and will factor into treatment 
decisions for the patient. Cognitive complaints include memory and thinking difficulties often 
seen in a variety of mental and physical illnesses, such as dementia. Activation may be assessing 
for what is seen in a manic phase of bipolar disorder. Disconstraint is a factor of impulse control 
disorders, such as attention-deficit/hyperactivity disorder, and is a known correlate of adherence 
to medical regimens. Substance abuse is important to assess for as it may be impacting other 
aspects of a patient’s physical health; it may also factor into a physician’s decision to prescribe 
medications which are commonly abused.  
The aim of the current study is to compare the MBHS’s nine scales of behavioral health 
problems to the MMPI-2-RF’s target scales and examine the correlations between each of the 
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scales. The second aim of the current study is to look at correlations between the PHQ-9 and the 
MMPI-2-RF’s scales. The use of the MBHS will compete with the currently widespread use of 
the PHQ-9. The primary use of the MBHS will be for the assessment of depression, and the 
appropriateness of medication will be dependent on the specific depression-related 
symptomology which is reported on the MBHS. Strong correlations between the MBHS and the 
targeted MMPI-2-RF scales are expected to be found, with lower correlations between the 
MBHS and non-targeted MMPI-2-RF scales.  
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METHOD 
 
Participants 
Participants were adult volunteers from the waiting room of a family medicine clinic, 
Mountain Area Health Education Center (MAHEC). Participants were required to be at least 18 
years old and able to read and understand English test materials prepared at approximately the 4th 
grade level. Participants were excluded from the study if they produced invalid MMPI-2-RF 
protocols using the standard cutoff scores of VRIN-r > 79, TRIN-r > 79, F-r = 120, or Fp >99. 
The goal of the study was to receive data from 450 participants. Participants were compensated 
for their time by receiving a $20 gift card to Walmart after completion of the study. 
Materials and Measures 
The Multidimensional Behavioral Health Screen (MBHS; McCord, Hickey, Mitchell, 
Warszawski, 2017) is an instrument currently being developed to be used to assess 
psychopathology constructs in primary medical care settings. The MBHS contains 27 short items 
which measure somatization, demoralization, anhedonia, anxiety, suicidal tendencies, activation, 
cognitive complaints, disconstraint, and substance misuse. Directions for each item read 
“Indicate your response to each item by circling the number. Please answer as accurately and 
honestly as you can.” Participants circle their response from a scale of 0-3, with 0 indicating 
definitely false, 1 indicating somewhat false, 2 indicating somewhat true, and 3 indicating 
definitely true. Total scores for each of the 9 constructs are calculated by adding the scores for 
the 3 items which comprise the scale. T-scores for each of the possible values are calculated 
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(found in Appendix C). Scores in the shaded area (T > 66) suggest need for referral to behavioral 
health for comprehensive assessment. Scores greater than one for suicidal ideation require 
immediate assessment. Preliminary data for the MBHS suggests strong reliability and validity. 
Validity was calculated previously using correlations between the MBHS scales and the MMPI-
2-RF target scales obtained from a college sample. Correlations between the MBHS scales and 
the MMPI-2-RF target scales for demoralization, anhedonia, and anxiety were .71, .57, and .66, 
respectively. 
The Patient Health Questionnaire-9 (PHQ-9; Spitzer, Kroenke, Williams, 1999) is a 
commonly used tool to assess for depression. The PHQ-9 is a 9-item self-report questionnaire 
which reflects the DSM-5 criteria for depression. For each item, participants answer on a scale of 
“0” (not at all) to “3” (nearly every day) how often they experience the 9 symptoms of 
depression. 
 The Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF; 
Ben-Porath & Tellegen, 2008/2011) is a frequently used tool for assessing psychopathology 
(Drayton, 2009). The MMPI-2RF consists of 338 self-report questions designed to conceptualize 
a person’s psychological state and personality. For the present study, the MMPI-2-RF’s nine 
scales of Somatic Complaints, Demoralization, Anhedonia, Dysfunctional Negative Emotions, 
Suicide/Death Ideation, Cognitive Complaints, Activation, Disconstraint, and Substance Abuse 
will be used as target criteria in evaluating the corresponding scales of the MBHS. 
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Procedures 
Data collection was completed at MAHEC, a primary care clinic for family medicine in 
the southeastern United States. The sample is composed of volunteers solicited in the waiting 
room of MAHEC. As noted above, volunteers must be 18 years of age, able to use a laptop, and 
proficient in English.  
Patients who express interest were given a consent form to read and sign. Then, they 
completed the PHQ-9, MBHS, and MMPI-2-RF on a laptop provided to them by the research 
assistant. The PHQ-9 and MBHS were given first to half the participants, and the MMPI-2-RF 
was administered first to the other half. This was done so that any potential priming effects of 
each questionnaire was counterbalanced. Completion of the three questionnaires took 
approximately one hour. The $20 gift card was awarded upon completion of the tasks. 
Participants were asked to sign a log indicating they received the gift card. Participants were 
given a second copy of the Consent Form which contained contact information for the 
researchers and the IRB. In this phase of the study, questionnaires were not scored immediately. 
Thus, no feedback was provided to the participant or to the MAHEC clinician.  
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RESULTS 
 
In the following sections we will present first the basic psychometrics findings for the 
MBHS, including reliability (Cronbach’s alpha and mean inter-item correlation for each scale), 
convergent validity (correlation with the MMPI-2-RF target scale), and discriminant validity 
(correlations with non-target MMPI-2-RF scales). Following this will be ROC-Curves, 
quantifying the accuracy of the screening scale to predict clinical-range elevations on the 
targeted scale of the MMPI-2-RF. Finally, we will examine parallel findings using the PHQ-9 as 
the predictive screener of clinical elevations on the MMPI-2-RF.  
Participants were excluded based on their Variable Response Inconsistency (VRIN) scale 
score on the MMPI-2-RF. The VRIN scale is indicative of random responses, with a score at or 
above 80 rendering the test uninterpretable. Similarly, the True Response Inconsistency (TRIN) 
scale score was used to exclude participants based on their propensity to always answer “true” or 
always answer “false” to questions. Scores at or above 80 on the TRIN scale indicate the 
participant was likely giving fixed responses. Consequently, 213 participants took part in the 
study, but only 134 participants remained once individuals with scores of 80 or higher on VRIN 
or TRIN were excluded.  
Reliability 
 Table 2 presents the mean inter-item correlation for the three items which comprise each 
of the MBHS subscales. These correlations are compared to the mean inter-item correlations for 
the items on the MMPI-2-RF subscales as a point of reference. The MBHS performed similarly 
to or better than the MMPI-2-RF in terms of inter-item correlations, substantiating the utility of 
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the items chosen to compose the MBHS scales. In a similar way, Cronbach’s alpha for the 
MBHS’s scales and the MMPI-2-RF’s scales are compared. Cronbach’s alpha for the MBHS was 
comparable to that of the MMPI-2-RF, suggesting strong reliability for the MBHS’s scales. 
Table 2: Inter-item correlations and Cronbach’s alpha for MBHS and MMPI-2-RF scales 
 Mean Inter-Item Correlation Cronbach’s Alpha 
 MBHS Scale [MMPI-2-RF] MBHS Scale [MMPI-2-RF] 
SOMs  [ RC1] .54 [.11] .78 [.76] 
DEMs [ RCd] .61 [.24] .83 [.88] 
ANHs   [ RC2] .51 [.10] .76 [.66] 
ANXs  [ RC7] .60 [.16] .82 [.82] 
SUIs   [ SUI] .57 [.16] .80 [.38] 
COGs  [ COG] .56 [.16] .79 [.67] 
ACTs   [ ACT] .37 [.15] .64 [.60] 
DSCs   [ DISCr] .52 [.14] .76 [.71] 
SUBs   [ SUB] .43 [.20] .69 [.62] 
 
Some differences between the inter-item correlations within the MMPI-2-RF and MBHS 
may be attributable to structural differences, including the MBHS’s 4-choice rubric and very 
short scale. Overall, our findings conclude that the MBHS performs as well as the MMPI-2-RF 
and that the MBHS has adequate internal reliability.  
Validity 
 Table 3 presents correlations between the MBHS’s 9 predictor scales and the MMPI-2-
RF target scales. High convergent validity was found for each scale, with almost every MBHS 
scale correlating the most highly with its target scale on the MMPI-2-RF. The MBHS also 
demonstrated strong discriminant validity, with few scales correlating more highly with a non-
target MMPI-2-RF scale than the target scale. Indeed, of the 81 correlations between the MBHS 
and the targeted MMPI-2-RF scales, 77 were in the predicted direction. The four exceptions were 
 
17 
 
largely based on actual correlations between underlying latent constructs and are quite 
distinguishable by item content. Higher convergent and discriminant validity was found for the 
MBHS than the PHQ-9. The PHQ-9 had high correlations with many MMPI-2-RF subscales and 
not only DEM, which is the most logical target scale for a depression screener. This 
demonstrates the diverse and heterogeneous constructs measured by the PHQ-9, evidencing 
further its lack of utility as a depression screener.   
Table 3: Correlations between MBHS predictors and MMPI-2-RF targets 
 RC1 RCd RC2 RC7 SUI COG ACT DISCr SUB 
SOMs .725 .593 .606 .473 .347 .565 .168 .029 .028 
DEMs .585 .744 .628 .653 .288 .434 .168 .204 .142 
ANHs .649 .704 .684 .649 .341 .538 .303 .141 .080 
ANXs .541 .707 .561 .677 .286 .411 .321 .147 .129 
SUIs .299 .393 .344 .385 .655 .235 .320 .071 .117 
COGs .579 .713 .488 .615 .327 .730 .425 .232 .155 
ACTs .353 .559 .306 .526 .397 .446 .501 .419 .246 
DSCs .167 .493 .261 .357 .280 .327 .498 .530 .474 
SUBs -.092 .187 .179 .278 .109 .038 .080 .650 .799 
          
PHQ-9 .60 .68 .56 .57 .39 .55 .28 .18 .14 
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Area Under the Curve (AUC) Receiver Operating Characteristics (ROC) Curves 
 ROC curves were created to determine the accuracy of the MBHS in differentiating 
clinical-range elevations and non-clinical scores on the target scale of the MMPI-2-RF. The ROC 
is a curve of probability, with the AUC measuring the degree to which the screener is able to 
distinguish between positive and negative classes. In the case of the MBHS, this describes 
clinical and non-clinical elevations on the MMPI-2-RF. The higher the AUC to 1, the greater 
ability of the screener to accurately predict the accurate outcome. An AUC of 0 describes a 
screener with no ability to distinguish between positive and negative classes, and an AUC of .5 
designates a screener with a random chance of distinguishing accurately. The closer to the upper-
left corner of the ROC the AUC line is, the higher the rate of true positives, indicating high 
sensitivity, and higher rates of true negatives, indicating high specificity.  
Because the MBHS is to function as a screening tool, it is imperative for it to be capable 
of accurately detecting clinical elevations. Table 4 presents the ROC curve for the ANH scale. 
The ANH scale of the MBHS had .86 AUC, indicating high likelihood of placing participants in 
the same category the MMPI-2-RF placed them in. A ROC Curve was completed for each of the 
MBHS scales, with classification accuracies ranging from an AUC value of .73 to .90. 
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Table 4: AUC values for the MBHS classification of MMPI-2-RF scores 
MBHS Scale AUC Probability Level 
SOMs .79 .000 
DEMs .89 .000 
ANHs .86 .000 
ANXs .80 .000 
SUIs   .73 .000 
COGs .90 .000 
ACTs  .74 .000 
DSCs   .82 .000 
SUBs .85 .000 
 
Table 5: ROC Curve between the MBHS and MMPI-2-RF classification of ANH 
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DISCUSSION 
 
The purpose of this study was to establish the MBHS as a viable alternative to the PHQ-9 
as a screening tool to be implemented within primary medical care facilities. The MBHS’s scales 
correlated highly with the MMPI-2-RF’s target scales, demonstrating high convergent validity. 
Furthermore, the MBHS demonstrated high discriminant validity as its scales correlated the most 
highly with its MMPI-2-RF target scale, and no other scale. Our findings substantiate the claim 
that the MBHS is accurately screening for the target constructs in the MMPI-2-RF.  
Our results indicated that the PHQ-9 does not have high discriminant or convergent 
validity with any of the nine constructs of the MMPI-2-RF. Thus, the PHQ-9 does not screen for 
any one construct, rather a muddle of symptomatology which is attributed to the construct of 
depression. The PHQ-9 does accurately predict depression diagnoses; however, the current 
paradigm shift provides ample evidence suggesting that current heterogeneous diagnoses have no 
meaningful implications for treatment or research. Furthermore, the reason mental illness 
prevention and treatment has remained stagnant may be attributable to the faulty labels which we 
are basing our diagnoses on. 
When looking at the implementation of the MBHS as part of a long-term study, a 
relationship between high ANH scores and the effectiveness of SSRIs is expected to be found. 
The ANH scale of the MBHS is linked to low positive emotions and a lack of joy, which may 
particularly improve through SSRI usage. Conversely, DEM, the MBHS scale which the PHQ-9 
correlates most highly with, may be predictive of low improvement of depressive symptoms 
following SSRI treatment. DEM may be less treatable through SSRIs since it is based more on 
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circumstantial variables, and less on neurochemistry. As SSRI effectiveness is highly variable, 
an effective method to screen for patients who would benefit the most from SSRIs would be 
greatly beneficial. Further research should explore if ANH is predictive of less depressive 
symptoms following SSRI treatment.  
One potential limit to the study was sample size. While data collection providing 
psychometric qualities for the MBHS will continue until a sample of 300 is reached, only 191 
participants were included for the present study. Of the 191 participants who partook in the 
study, usable data were collected on only 134 individuals. Researchers observed a notable 
portion of participants who finished the questionnaires improbably quickly given that most 
individuals take an hour to complete the three surveys. Participants were given a $20 incentive 
for completion of the study, which may have contributed to individuals completing the study 
who did not have the time or desire to do so accurately. Accordingly, data collection should 
continue increasing the sample size of usable data and consequently the power of the study.  
Another possible limitation of this study was the sample population. This study was 
conducted using English-speaking adults in a primary medical care setting. Further data should 
be collected on a more diverse sample. One limitation of collecting data in a primary care setting 
is that genuine, severe psychopathology is an outlier in the data set. However, a primary care 
setting is the target population for implementation of the MBHS.  
Despite the aforementioned limitations of the study, the MBHS has established itself to 
be a viable alternative to the PHQ-9. It is fitting that the mental health screeners administered in 
primary care settings reflect the growing propensity of psychologists to understand mental 
symptomatology as a dimension. Unlike other health screeners, the MBHS measures 9 core 
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constructs commonly presented in primary care settings, allowing physicians to have an accurate 
comprehensive depiction of psychological areas of concern for each patient. Hence, the MBHS 
can be recommended as a novel dimensional and homogenous mental health screener to be 
administered in primary care clinics. 
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Figure 1: The hierarchical dimensions within the MMPI-2-RF. 
 
 
 
 
 
 
 
 
 
 
Somatic/ 
Cognitive
Interpersonal 
Functioning
Broad
MLS               
Malaise
SUI     
Suicide/Death 
Ideation
INTR-r     
Introversion/ 
Low Positive 
Emotions
STW          
Stress/ Worry
JCP     
Juvenile 
Conduct 
Problems
AGG       
Aggression
FML            
Family Problems
GIC     
Gastrointestinal 
Complaints
HLP     
Helplessness/ 
Hopelessness
AXY          
Anxiety
SUB     
Substance 
Abuse
ACT       
Activation
RC3            
Cynicism
HPC               
Head Pain 
Complaints
SFD               
Self Doubt
ANP          
Anger 
Proneness
AGGR-r       
Aggressivness
IPP          
Interpersonal 
Passivity
NUC          
Neurological 
Complaints
NFC       
Inefficacy
BRF         
Behavior 
Restricting 
Fears
DISC-r       
Disconstraint
SAV                
Social Avoidance
COG          
Cognitive 
Complaints
MSF     
Multiple 
Specific Fears
SHY              
Shyness
NEGE-r     
Negative 
Emotionality/ 
Neuroticism
DSF     
Disaffiliativeness
Emotional/ Internalizing Thought Dysfunction
Behavioral/ 
Externalizing
THD                               
Thought Dysfunction
BXD                     
Behavioral/Externalizing 
Dysfunction
EID                           
Emotional/Internalizing Dysfunction
RC8     
Aberrant 
Experiences
PSYC-r     
Psychoticism
RC4     
Antisocial 
Behavior
RC9       
Hypomanic 
Activation
Narrow
Mid-level
RC1               
Somatic 
Complaints
RCd 
Demoralization
RC2            
Low Positive 
Emotions
RC7     
Dysfunctinal 
Negative 
Emotions
RC6          
Ideas of 
Persecution
 
24 
 
REFERENCES 
Coppen A. (1967). The biochemistry of affective disorders. British Journal of  
Psychiatry; 113:1237–64 
Cuthbert, B. N., & Insel, T. R. (2010). Toward new approaches to psychotic disorders: The  
NIMH Research Domain Criteria project. Schizophrenia Bulletin, 36, 1061–1062.  
http://dx.doi.org/10.1093/schbul/sbq108 
Cuthbert, B. N., & Kozak, M. J. (2013). Constructing constructs for psychopathology: The  
NIMH research domain criteria. Journal of Abnormal Psychology, 122, 928 –937.  
http://dx.doi.org/10.1037/a0034028 
Delgado, P., & Moreno, F. (2000). The role of norepinephrine in depression. Journal of  
Clinical Psychiatry, 61(1), 5-12.  
Der-Avakian, A., & Markou, A. (2012). The neurobiology of anhedonia and other reward- 
related deficits. Trends in Neurosciences, 35(1), 68-77. doi:10.1016/j.tins.2011.11.005 
Drayton M. (2009). Occupational Medicine, 59:135–136 doi:10.1093/occmed/kqn182 
Duman, R.S., Malberg, J., Nakagawa, S. & D’Sa, C. (2000). Neuronal plasticity and survival in  
mood disorders. Biological Psychiatry, 48, 732-739. 
Duman, S., Malberg J., Thome, J. (1999). Neural plasticity to stress and antidepressant treatment.  
Biological Psychiatry, 46:1181–1191. 
Fergusson, D., et al. (2005). Association between suicide attempts and selective serotonin  
reuptake inhibitors: systematic review of randomized controlled trials. British  
Medical Journal, Vol. 330, pp. 396–99. 
Few, L., et al., (2013). Supplemental Material for Examination of the Section III DSM-5  
Diagnostic System for Personality Disorders in an Outpatient Clinical Sample. Journal of  
Abnormal Psychology. doi:10.1037/a0034878.supp 
Fournier, J. C., Derubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., &  
Fawcett, J. (2010). Antidepressant drug effects and depression severity. Jama, 303(1),  
47. doi:10.1001/jama.2009.1943 
 
25 
 
Goldstein, B. J., & Goodnick, P. J. (1998). Selective serotonin reuptake inhibitors in the  
treatment of affective disorders- III. Tolerability, Safety and Pharmacoeconomics.  
Journal of Psychopharmacology, 12(4). 
Gueorguieva, R. (2011). Trajectories of depression severity in clinical trials of duloxetine.  
Archives of General Psychiatry, 68(12), 1227. 
Harvard Health Publishing. (2018). What are the real risks of antidepressants? 
https://www.health.harvard.edu/newsletter_article/what-are-the-real-risks- 
of-antidepressants 
Katzman, M., & Sternat, T. (2016). Neurobiology of hedonic tone: The relationship between  
treatment-resistant depression, attention-deficit hyperactivity disorder, and substance  
abuse. Neuropsychiatric Disease and Treatment, Volume 12, 2149-2164.  
doi:10.2147/ndt.s111818 
Kegler, S. R., Stone, D. M., & Holland, K. M. (2017). Trends in suicide by level of  
urbanization-United States, 1999–2015. MMWR. Morbidity and Mortality Weekly  
Report, 66(10), 270-273. 
Kirsch, I. (2008). Antidepressants and the placebo response. Public Library of Science Medicine,  
18(04), 318-322. 
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9. Journal of General Internal  
Medicine, 16(9), 606-613. doi:10.1046/j.1525-1497.2001.016009606.x 
Kotov, R., Ruggero, C. J., Krueger, R. F., Watson, D., Yuan, Q., & Zimmerman, M. (2011). New  
dimensions in the quantitative classification of mental illness. Archives of general  
psychiatry, 68(10), 1003-1011. 
Kotov, R., et al., (2017). Supplemental Material for The Hierarchical Taxonomy of  
Psychopathology (HiTOP): A Dimensional Alternative to Traditional Nosologies.  
Journal of Abnormal Psychology. doi:10.1037/abn0000258.supp 
Magellan Healthcare (2014). Treating Depression in the primary care setting. Retrieved March 
12, 2018, from https://www.magellanprovider.com/media/11790/f-pce10-pcp-dep.pdf 
 
26 
 
McCord, D. M., Haugh, S., & Hutchinson, K. (2017, March). Preliminary development of a 
multi-band behavioral health screen. Paper presented at the annual meeting of the 
Southeastern Psychological Association, Atlanta, GA. 
McCord, D. M., Hickey, H., Mitchell, H., Warszawski, J. (2017, March). Update on the 
development of the Minnesota Behavioral Health Screen. Paper presented at the annual 
meeting of the Southeastern Psychological Association, Atlanta, GA. 
McCord, D. M., Provost, R. P., Scales, W. D., & McCord, J. T. (2015, June). Mapping the PHQ-
9 depression screening tool onto the construct-relevant scales of the MMPI-2-RF. Poster 
session presented at the 50th Annual Symposium on Recent Research with the MMPI-2-RF, 
MMPI-2, and MMPI-A, Minneapolis, MN. 
Mojtabai, R., & Olfson, M. (2011). Proportion of antidepressants prescribed without a 
psychiatric diagnosis is growing. Health Affairs, 30(8), 1434-1442. 
National Institute of Mental Health (2018). Major Depression. Retrieved March 12, 2018, from 
https://www.nimh.nih.gov/health/statistics/major-depression.shtml 
Pizzagalli, D. A., Iosifescu, D., Hallett, L. A., Ratner, K. G., & Fava, M. (2008). Reduced 
hedonic capacity in major depressive disorder: Evidence from a probabilistic reward task. 
Journal of Psychiatric Research, 43(1), 76-87. doi:10.1016/j.jpsychires.2008.03.001 
Regier D., Narrow W., Clarke D., Kraemer H., Kuramoto S., Kuhl E., Kupfer D., (2013). DSM-5 
field trials in the United States and Canada, Part II: test-retest reliability of selected 
categorical diagnoses. The American Journal of Psychiatry; 170(1):59–70. 
 
27 
 
Sellbom, M., Ben-Porath, Y. S., & Bagby, R. M. (2008). On the hierarchical structure of mood 
and anxiety disorders: confirmatory evidence and elaboration of a model of temperament 
markers. Journal of Abnormal Psychology, 117(3), 576. 
Spitzer R., Kroenke, K., Williams, J. (1999). Validation and utility of a self-report version of  
PRIME-MD: the PHQ primary care study. Journal of the American Medical  
Association, 282, 1737-1744. 
Smith MA, Makino S, Kvetnansky R. (1995). Stress alters the expression of brain- 
derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. Journal of  
Neuroscience, 15:1768–1777. 
Watson, D., Gamez, W., & Simms, L. J. (2005). Basic dimensions of temperament and their  
relation to anxiety and depression: A symptom-based perspective. Journal of Research in  
Personality, 39, 46–66.doi:10.1016/j.jrp.2004.09.006  
World Health Organization (2018). Suicide Data. Retrieved March 12, 2018, from  
http://www.who.int/mental_health/prevention/suicide/suicideprevent/en/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
Appendix A 
Multidimensional Behavioral Health Screen (beta 8) 
 
ID: ____________________________ Age: _____  Gender: ________      Date: ____________________ 
Indicate your response to each item by circling the 
number. Please answer as accurately and honestly as you 
can.  
Definitely 
False 
Somewhat 
False 
Somewhat 
True 
Definitely 
True 
1. I have pains. 0 1 2 3 
2. I feel useless. 0 1 2 3  
3. There is little joy in my life. 0 1 2 3  
4. I worry a lot. 0 1 2 3  
5. I have thought about killing myself. 0 1 2 3  
6. I have trouble concentrating. 0 1 2 3  
7. I get bored easily. 0 1 2 3  
8. I often make impulsive decisions. 0 1 2 3  
9. I sometimes drink too much alcohol. 0 1 2 3  
 
Definitely 
False 
Somewhat 
False 
Somewhat 
True 
Definitely 
True  
10. I feel weak. 0 1 2 3  
11. I am dissatisfied with my life. 0 1 2 3  
12. I have little motivation. 0 1 2 3  
13. Nervousness interferes with my daily functioning. 0 1 2 3  
14. I have tried to kill myself. 0 1 2 3  
15. I get distracted easily. 0 1 2 3  
16. My thoughts race through my head very fast. 0 1 2 3  
17. I often break rules, regardless of the consequences. 0 1 2 3  
18. I currently use drugs/alcohol. 0 1 2 3  
 
Definitely 
False 
Somewhat 
False 
Somewhat 
True 
Definitely 
True  
19. I get nauseous. 0 1 2 3  
20. I feel generally discouraged. 0 1 2 3  
21. I tend to avoid social activities. 0 1 2 3  
22. I obsess about things I can’t control. 0 1 2 3  
23. I want to die. 0 1 2 3  
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24. I can’t remember things. 0 1 2 3  
25. I do dangerous things for thrills. 0 1 2 3 
 
26. I don’t think before I act. 0 1 2 3 
 
27. I have used drugs/alcohol in the past. 0 1 2 3 
 
                                              Copyright 2018, David M. McCord, Ph.D. 
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Appendix B 
Patient Health Questionnaire-9 
Name ______________________ Date _________ 
Over the last 2 weeks, how often have you been 
bothered by any of the following problems? 
Not 
at all 
Several 
days 
More 
than half 
the days 
Nearly 
every 
day 
1. Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless 0 1 2 3 
3. Trouble falling or staying asleep, or sleeping too 
much 
0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. Feeling bad about yourself—or that you are a failure 
or have let yourself or your family down 
0 1 2 3 
7. Trouble concentrating on things, such as reading the 
newspaper or watching television 
0 1 2 3 
8. Moving or speaking so slowly that other people 
could have noticed? Or the opposite—being so fidgety 
or restless that you have been moving around a lot 
more than usual 
0 1 2 3 
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9. Thoughts that you would be better off dead or of 
hurting yourself in some way 
0 1 2 3 
(For office coding: Total Score ____ = ____ + ____ + ____) 
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
Not difficult at all Somewhat difficult Very difficult Extremely difficult 
□ □ □ □ 
From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME‐MD 
PHQ). Copyright 1999 Pfizer Inc. 
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Appendix C 
Name/ID: ______________________________________________ 
 
Copyright 2018, David M. McCord, Ph.D. 
T-score SOM DEM ANH ANX SUI COG ACT DSC SUB %ile
> 90
88
86
84
82
80 8
78
76 9 7
74 9
72 9 8 8 >99
70 7 8 7 98
68 7 9 7 96
66 6 8 8 7 6 95
64 7 6 6 92
62 7 4 6 5 88
60 5 84
58 6 3 6 5 79
56 73
54 5 4 66
52 4 58
50 4 3 50
48 3 2 3 1 2 42
46 2 34
44 2 1 2 0 1 27
42 1 21
40 1 1 0 16
38 0 12
< 36 0 0 < 8
Raw Score
SOM DEM ANH ANX SUI COG ACT DSC SUB
1+10+19 2+11+20 3+12+21 4+13+22 5+14+23 6+15+24 7+16+25 8+17+26 9+18+27
DEMoralization, unhappiness, dissatisfaction COGnitive issues, attention, memory, focus
ANHedonia, inability to experience pleasure ACTivation, energy, restlessness
ANXiety, fear, worry DiSConstraint, impulsivity, low self-control
SUIcidal Tendencies, thoughts, attempts SUBstance Misuse - drug and/or alchohol
4
8
9
7
0
1
2
3
4
5
0
4
5
6
8
0
3
4
5
T score of 50 is general population mean. T-score of 63 or greater is clinical range (top 10% of medical 
outpatients). Scores in shaded areas suggest need for referral to Behavioral Health for comprehensive 
assessment. Score >  0 on SUI should be queried, and score > 4 requires formal assessment.
SOMatization, malaise, physical complaints
5
0
1
2
3
4
2
1
2
3
3
Multidimensional Behavioral Health Screen Profile Sheet (beta 8)
8
9
9
5
6
9
9
